Correlation Between Minimum Inhibitory Concentration and Clinical Outcome of Invasive Fusariosis
NCT ID: NCT04982159
Last Updated: 2022-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
11 participants
OBSERVATIONAL
2020-01-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors
NCT04738955
Markers of Infection and Resistance in Invasive Fusariosis
NCT04937751
Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
NCT00004938
Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
NCT01344681
Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
NCT02714504
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Invasive Fusariosis
Patients hospitalized with an invasive fusariosis diagnostic in the stablished period of study.
There is no intervention. This is an observational study.
There is no intervention. This is an observational study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
There is no intervention. This is an observational study.
There is no intervention. This is an observational study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Proof of anti-fungic susceptibility according to EUCAST or CLSI, for the medicine used in the treatment of invasive fusariosis.
* Available data about anti-fungic medicines used: name of medicine, start and end date of treatment.
* Available information about clinical outcome of illness after 30 days, 6 weeks and 90 days (dead or alive).
* Only cases of invasive fusariosis proven or possible will be included.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maimónides Biomedical Research Institute of Córdoba
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitario Reina Sofía
Córdoba, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIB-VOR-2019-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.